EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, WuXi Biologics (Cayman)'s Enterprise Value is $17,088 Mil.
WuXi Biologics (Cayman)'s Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $370 Mil. Therefore, WuXi Biologics (Cayman)'s EV-to-FCF for today is 46.16.
The historical rank and industry rank for WuXi Biologics (Cayman)'s EV-to-FCF or its related term are showing as below:
WXIBF'
s EV-to-FCF Range Over the Past 10 Years
Min: -861.18 Med: -82.79 Max: 261.43
Current: 44.31
During the past 12 years, the highest EV-to-FCF of WuXi Biologics (Cayman) was 261.43. The lowest was -861.18. And the median was -82.79.
WXIBF's EV-to-FCF is ranked worse than 76.74% of 331
companies
in the Biotechnology industry
Industry Median: 15.9
vs WXIBF: 44.31
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
WuXi Biologics (Cayman)'s PE Ratio (TTM) for today is calculated as:
WuXi Biologics (Cayman)'s share price for today is $4.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. WuXi Biologics (Cayman)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.164.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s EV-to-FCF distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s EV-to-FCF falls into.
WuXi Biologics (Cayman)'s current Enterprise Value is $17,088 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. WuXi Biologics (Cayman)'s Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $370 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) (WXIBF) has a EV-to-FCF of 46.16 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on WuXi Biologics (Cayman) and its competitors. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #254 out of 331 companies in the Biotechnology industry, placing it in the top 76.7%.
Is WuXi Biologics (Cayman)'s EV-to-FCF too high?
WuXi Biologics (Cayman)'s current EV-to-FCF is 46.16. The Biotechnology industry median EV-to-FCF is 15.90. WuXi Biologics (Cayman)'s value of 46.16 is 190.3% above this industry median. Based on the distribution chart, WuXi Biologics (Cayman) ranks #254 out of 331 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, WuXi Biologics (Cayman) has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #254 out of 331 companies for EV-to-FCF. This places WuXi Biologics (Cayman) in the lower half of its industry. The industry median EV-to-FCF is 15.90. WuXi Biologics (Cayman)'s value of 46.16 is 190.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.90, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi Biologics (Cayman)'s current EV-to-FCF of 46.16 is 190.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on WuXi Biologics (Cayman) and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi Biologics (Cayman)'s current EV-to-FCF is 46.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.11, compared to a current price of $4.00 — trading 21.7% below its estimated fair value. The current EV-to-FCF is 46.16 and 190.3% above the Biotechnology industry median of 15.90. WuXi Biologics (Cayman)'s overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current EV-to-FCF is 46.16 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued.
The current stock price of $4.00 is trading 21.7% below its estimated GF Value™ of $5.11.
GuruFocus considers WuXi Biologics (Cayman) to be Modestly Undervalued.
Key valuation signals for WXIBF:
EV-to-FCF: 46.16
GF Value™: $5.11 vs. price of $4.00 (21.7% below fair value)
Industry Position: 190.3% above the Biotechnology median (#254 of 331)
No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
97GF Score
Get the complete analysis for WXIBF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WXIBF has been successfully added to your 
